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Background: Alpha 1- antitrypsin (α1AT) belongs to the superfamily of serpins and inhibits different proteases.
α1AT protects the lung from cellular inflammatory enzymes. In the absence of α1AT, the degradation of lung tissue
results to pulmonary complications. The pulmonary route is a potent noninvasive route for systemic and local
delivery. The aerosolized α1AT not only affects locally its main site of action but also avoids remaining in circulation
for a long period of time in peripheral blood. Poly (D, L lactide-co glycolide) (PLGA) is a biodegradable and
biocompatible polymer approved for sustained controlled release of peptides and proteins. The aim of this work
was to prepare a wide range of particle size as a carrier of protein-loaded nanoparticles to deposit in different parts
of the respiratory system especially in the deep lung. Various lactide to glycolide ratio of the copolymer was used
to obtain different release profile of the drug which covers extended and rapid drug release in one formulation.
Results: Nonaqueous and double emulsion techniques were applied for the synthesis of nanoparticles.
Nanoparticles were characterized in terms of surface morphology, size distribution, powder X-ray diffraction (XRD),
encapsulation efficiency, in vitro drug release, FTIR spectroscopy and differential scanning calorimetry (DSC). To
evaluate the nanoparticles cytotoxicity, cell cytotoxicity test was carried out on the Cor L105 human epithelial lung
cancer cell line.
Nanoparticles were spherical with an average size in the range of 100 nm to 1μ. The encapsulation efficiency was
found to be higher when the double emulsion technique was applied. XRD and DSC results indicated that α1AT
encapsulated in the nanoparticles existed in an amorphous or disordered-crystalline status in the polymer matrix.
The lactic acid to glycolic acid ratio affects the release profile of α1AT. Hence, PLGA with a 50:50 ratios exhibited
the ability to release %60 of the drug within 8, but the polymer with a ratio of 75:25 had a continuous and longer
release profile. Cytotoxicity studies showed that nanoparticles do not affect cell growth and were not toxic to cells.
Conclusion: In summary, α1AT-loaded nanoparticles may be considered as a novel formulation for efficient
treatment of many pulmonary diseases.
Keywords: Cytotoxicity, DSC (differential scanning calorimetry), FTIR, Nanoparticle, Sustained drug release, XRD
(x-ray diffraction)* Correspondence: hasannia@modares.ac.ir
2Faculty of Biological Sciences, Tarbiat Modares University, Jalal Ale Ahmad
Highway, P.O.Box: 14115-111, Tehran, IR, Iran
3National Institute of Genetic Engineering and Biotechnology, Tehran, IR, Iran
Full list of author information is available at the end of the article
© 2012 Pirooznia et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Pirooznia et al. Journal of Nanobiotechnology 2012, 10:20 Page 2 of 15
http://www.jnanobiotechnology.com/content/10/1/20Background
Alpha 1- antitrypsin (α1AT) is a 54 kDa glycoprotein
which belongs to the superfamily of serpin. The protein
inhibits serine protease and a broad group of other pro-
teases. It protects the lungs from cellular inflammatory
enzymes, especially elastase, therefore it is known as the
human neutrophil elastase inhibitor [1,2]. In the absence of
α1AT, the neutrophil elastase released by lung macro-
phages, is not inhibited, thus leading to elastin breakdown
and the loss of lung elasticity. This causes degradation of
the lung tissue resulting in pulmonary complications, such
as emphysema or chronic obstructive pulmonary disease
COPD in adults [3,4]. Impaired α1AT secretion in liver and
accumulation in liver cells also causes cirrhosis in infants
[5,6]. Relation between α1AT deficiency and various dis-
eases including asthma, rheumatoid arthritis, anterior uve-
itis and systemic lupus erythematosus has also been
reported [7-9]. α1AT is not only an anti-inflammation pro-
tein but also an immune system regulator which regulates
lymphocyte proliferation and cytotoxicity, mediates mono-
cyte and neutrophil functions. Besides antiapoptotic func-
tion in the lung epithelial cells in vitro [10], has broad anti-
inflammatory effects in humans [11]. It has been shown
that protease-antiprotease imbalance is an important factor
in the pathogenesis of COPD and other pulmonary dis-
eases, such as bronchitis. In this process, an exogenous
proteolytic enzyme leads to lung tissue breakdown (be-
cause human neutrophil elastase cannot be inhibited by
α1AT) [12,13]. Furthermore, α1AT can act as a tumor sup-
pressor by inhibiting the growth of breast cancer cells [14].
The treatment of cystic fibrosis (CF) patients with
aerosolized α1AT has been shown to reduce sputum
neutrophil numbers, IL-8 concentration and elastase
function [15]. The effect of α1AT on IL-8 as a neutrophil
chemoattractant and a neutrophil recruiter to the lung is
also important because neutrophils are considered as the
main cause of COPD pathogenesis and clinical effects of
α1AT in COPD are obvious [16].
A recent study has shown that α1AT can slow down
the loss of insulin producing cells in diabetic patients
who are at the early stages of disease. This study, which
is in phase II of clinical trials, demonstrates the effect of
α1AT in preservation of β-cells, function to produce in-
sulin [17,18].
The commercially available plasma derived product of
α1AT is administered intravenously. Such an intravenous
augmentation therapy has disadvantages, such as high
costs, viral contaminations and immune reactions be-
cause of prolonged retention of the drug in circulation.
The pulmonary route is an alternative, potent and non-
invasive route for systemic and local delivery of macro-
molecules. The aerosolized α1AT not only affects locally
the lung, its main site of action, but also avoid remaining
and circulation for a long time in peripheral blood [19].This route of administration provides large surface
area, thin epithelial barrier, avoids first-pass metabolism
and high blood flow. Many proteins and peptides have
been delivered to the lung successfully in this way
[20,21]. In fact spherical materials less than 10 μ in diam-
eter can be inhaled. Particles less than 2.5 μ can reach
the alveoli. Nanoparticles less than 100 nm are mainly
deposited in the alveolar region. Nano-sized particles
avoid macrophage pulmonary clearance and cross with-
out active uptake [22].
The aerosolized α1AT is currently under study [8,23].
In the aerosol form, 25%-45% of aerosolized particle
reaches the respiratory system, however in the intraven-
ous infusion only 10%-15% of α1AT reaches to this site.
The aerosolized α1AT not only affects its main site of
action locally, but also avoids remaining in circulation
for a long period of time in peripheral blood, thus avoid-
ing immune response reactions because of long-term
use of α1AT [20,21].
Nevertheless, for the purpose of drug delivery, PLGA
(poly- D, L lactide-co glycolide) is the best candidate.
PLGA-based nanotechnology has gained tremendous
interest in medical applications such as sustained drug
release, drug delivery, diagnostics and treatment [24].
Polylactide (PLA) and its copolymers that contain glyco-
lide (PLGA) have been approved by the US food and
drug administration (FDA) for the purpose of drug deliv-
ery. PLGA is an ideal choice for drug delivery because of
its unique properties including biocompatibility, bio-
availability and variable degradation kinetics, high drug-
loading capability, stability and extended drug release
over other carriers such as liposomes [25-28]. PLGA
protects the encapsulated drug from enzymatic degrad-
ation and changes the pharmacokinetics of the drug. It
provides a wide range of degradation rates, from months
to years, depending upon its composition and molecular
weight [27]. FDA has approved products using PLGA as
carriers which include Nutropin Depot for growth defi-
ciencies, Sandostatin LAR for acromegaly and Trelstar
Depot for prostate cancer [29]. At present many other
PLGA-based formulations are also at the pre-clinical stage.
The biodegradation rate of PLGA polymers is dependent
on the lactide/glycolide, molecular weight, degree of crys-
tallinity and the transition glass temperature (Tg) of the
polymer [30]. The release profile of PLGA nanoparticles
can be divided into 4 different phases: initial burst, induc-
tion period, slow release period and final release period
[31]. Polymers containing a 50:50 ratios of lactic and gly-
colic acid have faster hydrolytic activities than those with
other ratios of the monomers. PLGA nanoparticles can be
used safely for oral, nasal, pulmonary, parenteral, transder-
mal and intra-ocular routes of administration [32]. The
PLGA nanoparticles can be prepared by different techni-
ques. The most common technique is the emulsification
Pirooznia et al. Journal of Nanobiotechnology 2012, 10:20 Page 3 of 15
http://www.jnanobiotechnology.com/content/10/1/20solvent evaporation technique because of its simplicity
and high encapsulation efficiency. The single emulsion
method is only suitable for hydrophobic drugs and leads
to very poor encapsulation efficiency with regard to pro-
tein or peptide drugs. The oil-in-oil (o/o) emulsification
technique which is known as the nonaqueous emulsion
method is a new and efficient method for encapsulation of
hydrophilic drugs. The double emulsion method is also
suitable for encapsulating hydrophilic drugs with high effi-
ciency [20,33,34].
In this work, we prepared α1AT-loaded nanoparticles
with two different methods and studied the release prop-
erties of nanoparticles at different ratios of lactide/glyco-
lide. The polydispersity of nanoparticles is an important
factor in this work due to the lung's anatomy.
Finally the nanoparticles which were prepared by the
double emulsion technique were mixed to obtain a 50:50
and 75:25 ratios of nanoparticles fabricated with PLGA.
In this way the capabilities of the mixture was explored
for the simultaneous prolonged and high initial burst re-
lease of the drug.Results and discussion
Image analysis
The SME graphs revealed the particle size and surface
morphology of protein-loaded PLGA nanoparticles with
copolymer ratio of lactide: glycolide 50:50 and 75:25.
The morphology of nanoparticles prepared by double
and nonaqueous emulsion technique was spherical. Pro-
tein loaded-particles have smooth surface with few
indents that can be because of α1AT incorporation.
Results showed that particles have nano range size ~350
nm. Micrographs of freeze-dried nanoparticles without
any stabilizer such as sorbitol showed that PLGA nano-
particles have the tendency to form aggregates; therefore
in preparation process sorbitol 1% (w/v) was added in
the final step before lyophilization. The initial and final
particles mean size and distribution were identical before
and after freeze-drying process (Figure 1).Particle size and distribution
The particle size distribution of prepared nanoparticle
by nonaqueous and double emulsion techniques and dif-
ferent lactide: glycolide ratio is summarized in Figure 2.
Preparation method affects particle size and distribution.
Particles produced by nonaqueous emulsion technique
have smaller size and wider size distribution. Nanoparti-
cles obtained by double w/o/w technique have slightly
bigger size and narrower distribution. Although the
polymer ration has no effect on particle size and its dis-
tribution. α1AT-loaded PLGA (50:50 and 75:25) nano-
particles produced by double emulsion technique have
similar size and particle distribution (Figure 2).The X-Ray diffraction (XRD)
The XRD results showed a peak between 3° and 5° (2)
which correspond to the semi crystalline state for the
α1AT protein. Results indicate that α1AT in nanoparti-
cles has an amorphous or disordered-crystalline state
which can possibly be due to the protein distribution in
polymer matrix. No peak was observed for PLGA with
different ratio which indicates that PLGA is an amorph-
ous copolymer (Figure 3).
Loading efficiency
The encapsulation yield was calculated by the following
equation:
Encapsulation efficiency %ð Þ ¼
Theprotein loaded nanoparticleweight  protein concentrationafter hydrolysing
The initail amount of proteinaddedduring synthesis
 100
Protein concentration after hydrolyzing by fluoromet-
ric method and encapsulation yield was as shown in
Table 1.
As a result, the double emulsion technique for the
preparation of nanoparticles leads to a higher entrap-
ment efficiency of α1AT. Results showed that difference
in encapsulation efficiency was not significant for PLGA
50:50 and 75:25, therefore the copolymer ratio does not
affect the drug encapsulation efficiency.
In vitro release
The standard curve was generated using a series of dilu-
tions ranging from 2.5 to 200 μg/ml of α1AT. The con-
centration of the released protein was determined using
intrinsic fluorescence of aromatic amino acids. This
technique is suitable for quantitating protein concentra-
tions of less than 10μg/ml Fluorescence was measured
using excitation/emission wavelengths of 280/332nm.
The intensity of fluorescence correlates to the protein
concentration (Figure 4 and Table 2).
Protein polymer interaction study
The FTIR spectra of α1AT, PLGA 50:50 and 75:25,
α1AT- loaded PLGA (50:50 and 75:25) show that there
were no changes in the position of absorption peaks.
The pure AAT sample (Figure 5a) showed the main
peaks contributed by the functional groups of molecule
such as carbonyl –C=O stretching (1650 cm-1), –OH
stretching (3300-3500 cm-1), –CH twisting (900-1000
cm-1). The pure PLGA 50:50 (Figure 5b) and 75:25 sam-
ples (Figure 5c) showed peaks such as OH stretching
(3200-3500 cm-1), –CH (2850-3000 cm-1), carbonyl
–C=O stretching (1700-1850 cm-1) and C–O stretching
(1050-1250 cm-1). AAT-loaded nanoparticles using non-
aqueous emulsion (Figure 5d) and double emulsion
technique with PLGA 50:50 and 75:25 (Figure 5e and f)
Figure 1 Typical SEM image of AAT-loaded (a, b, c, d, f, g and h) and unloaded nanoparticles (e).
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their separated components in the infrared spectra.
Spectral analysis indicated that the specific functional
groups of polymeric material in the nanoparticles surface
have almost the same chemical characteristics of the
pure polymer. The study suggests that molecular inter-
actions that could alter the chemical structure of the
drug did not occur. Therefore, no chemical interaction
between functional group of protein and polymer exist
(Figure 5).
Differential Scanning Calorimetry measurement
The DSC curves for PLGA 50:50, PLGA 75:25 and α1AT-
loaded PLGA nanoparticles prepared using the nonaqu-
eous and double emulsion method were detected and
shown in Figure 6. α1AT exothermal peak were not
present in α1AT-loaded nanoparticles which indicate that
no crystalline α1AT was found in nanoparticles. The simi-
lar melting transition properties of loaded and unloadednanoparticles show the PLGA polymer remained un-
affected during encapsulation. The DSC thermograms of
pure PLGA materials and α1AT-loaded nanoparticles were
shown in Figure 6.
Evaluation of Cytotoxicity
In this study, cell cytotoxicity of α1AT- loaded nanopar-
ticles was evaluated using Cor L105 lung epithelial-like
cells. The results show that the viability of cells treated
with different concentrations of free and loaded nano-
particles remains unchanged and cells retained more
than 80% of their viability. Furthermore, the morphology
of cells before and after treatment with nanoparticles
was similar (Figure 7).
Discussion
α1AT inhibits a broad range of proteases and protects the
lung from neutrophil elastase during inflammation or in-
fection [1,2]. This inhibitor is an acute phase protein the
Figure 2 mean particle size of nanoparticle prepared with nonaqueous (a), double emulsion technique using PLGA 50:50 (b) and 75:25 (c).
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inflammation [15]. The absence or inefficient function of
α1AT in the lungs leads to uncontrolled function of elas-
tase and elastin breakdown, resulting in respiratory pro-
blems such as COPD and emphysema [3,4,5]. Association
between α1ATand a number of diseases including asthma,
rheumatoid arthritis, anterior uveitis and systemic lupus
erythematosus suggests that α1AT is not only an anti-in-
flammatory protein but also an immune system regulator
[7-9]. α1AT regulates lymphocyte proliferation and cyto-
toxicity, mediates monocyte and neutrophil functions. Be-
sides, researchers have shown that the protease-
antiprotease imbalance is an important factor in thepathogenesis of COPD and other pulmonary diseases,
such as bronchitis. COPD is one of the most important
causes of irreversible lung damage and thus the fourth
most common cause of death in the U.S. In this process,
exogenous proteolytic enzymes lead to lung damage. Be-
sides different physiological roles of α1AT including the
control of insulin secretion, antiprotease activity, pro-
tecting β-cells against cytokine-induced apoptosis, act-
ing as an anti-inflammation compound [14,15,16], it is
also regarded as an antiapoptotic factor in lung epithe-
lial cells [9]. A recent study has shown that α1AT can
slow down the loss of insulin producing cells in diabetic
patients who are at the early stages of disease. This
Figure 3 XRD spectra of PLGA 50:50 (a), PLGA 75:25 (b), AAT- loaded PLGA nanoparticle prepared using nonaqueous emulsion
technique (c), AAT- loaded nanoparticle prepared using double emulsion technique containing PLGA 50:50 (d) and AAT- loaded
nanoparticle prepared using double emulsion technique containing PLGA 75:25 (e).
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the effect of α1AT in preservation of β-cells' function
[17,18]. Therefore, only with appropriate and adequate
concentrations of α1AT the lungs' correct function can
be maintained. One of the treatment strategies for
optimum activity of α1AT during inflammation is re-
placement therapy using intravenous infusion (Prolas-
tin, Zemaira, Aralast and Glassia) [1,6]. In the infusion
form, only 10%-15% of α1AT reaches the target organ.
Another possible treatment strategy is through airway
delivery. In this form of treatment not only the
aerosolized α1AT directly reaches the target organ, but
also prevents the accumulation of excess drug in the
blood, therefore, a much lower level of drug is required
[25,26]. Also immune reactions arising from the reten-
tion of drug in the peripheral circulation are avoided.Table 1 Encapsulation efficiencies applying different













75:25 0.39 % 92.2 ± 5.5
Double emulsion
technique
50:50 0.27 % 94.6 ± 5.5
Nonaqueous emulsion
technique
50:50 0.6 % 88 ± 5.5Besides the different forms of α1AT which are all
plasma-derived products and have disadvantages, such as
viral contaminations and high costs, the recombinant
forms of α1AT derived from eukaryotic hosts such as
yeast, are currently under study as a therapy for α1AT de-
ficiency [35], however, these are not yet commercially
available. Furthermore, in addition to the development
and optimization of recombinant forms of α1AT, efforts
on packaging α1AT in micro- and nanoparticles for pul-
monary delivery are also under investigations. The lung
tissue has been mainly used as a delivery route for many
drugs because of its unique anatomical and physiological
properties. With the development of new inhaler devices,
the role of the lung tissue in drug delivery becomes more
important and dominant. In addition to chemical drugs,
especially for the treatment of pulmonary diseases, deliv-
ery of macromolecules such as different antibodies and
hormones are also part of the research of many pharma-
ceutical companies [26].
Various antibodies, and insulin, which are now objec-
tives at different phases of clinical trials, are examples of
such medicines.
The pulmonary drug delivery strategies for protein
and peptide-based medicines are based on using parti-
cles with a lipid origin (liposomes) and that are poly-
meric (PLGA, Chitosan) [20,24].
Besides the type of particle, physicochemical properties
such as surface charge, size and stability are important
factors in the selection of particles for lung drug delivery
Figure 4 In vitro release profile of α1AT from PLGA nanoparticles with different ratio synthesized by nonaqueous and double
emulsion technique.
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for controlled and sustained drug delivery because it is a
biocompatible, bioavailable and stable polymer that is
not toxic to cells [20-25-31]. Various peptides and chem-
ical drugs are delivered with PLGA, such as rifampicin,
isoniazid, pyrazinamide, nuclear factor κB decoy oligo-
deoxynucleotide [36].
Like oral drug delivery, for pulmonary delivery the car-
rier must be biocompatible, small to pass through the
intestinal barrier (M cell), have size dispersity, physical
stability and higher encapsulation efficiency [37,38].
α1AT involves being internalized by endothelial cells
mostly by the process of clathrin-mediated endocytosis.Table 2 Fluorescence intensity of protein release at
different time intervals from PLGA nanoparticles which












0 0 0 0
8 7.69 9.33 6.65
24 8.38 9.54 7.81
30 8.64 9.94 8.69
48 9.61 11.58 10.54
72 10.9 11.99 12.38
96 11.58 12.74 14.74
120 11.89 12.95 15.02
240 12.12 13 15.31In the case of particle uptake, clathrin-coated pits ex-
pand and enclose particles of around 200 nm [38]. In
addition, particles with an aerodynamic diameter of less
than 0.1μm are able to reach the deepest regions of the
lung, the alveoli [39].
The emulsification solvent evaporation technique is
another common process for the synthesis of PLGA
nanoparticles because of its simplicity and high encapsu-
lation efficiency. The single emulsion method is only
suitable for hydrophobic drugs and is not efficient for
protein or peptide drugs. The oil-in-oil (o/o) emulsifica-
tion technique which is known as a nonaqueous emulsion
method is a new and efficient method for encapsulation of
hydrophilic drugs. The double emulsion method is also
known as a suitable procedure for encapsulating hydro-
philic drugs with high efficiency [20,33,34]. Particle size
plays an important role in lung deposition, along with
particle velocity and settling time. As particle size
increases above 3 μm, there is a shift in aerosol depos-
ition from the periphery to the conducting airways.
Oropharyngeal deposition also increases as particle sizes
increase above 6 μm. Exhaled loss is high with very
small particles of 1 μm or less. These data support the
view that particle sizes of 1-5 μm are best for reaching
the lung periphery, while 5-10 μm particles deposit pre-
ferentially in the conducting airways.
Aerosol devices in clinical use produce heterodisperse
(also termed polydisperse) particle sizes, meaning that
there is a mix of sizes in the aerosol. This is contrasted
with monodisperse aerosols aerosols, which consist of a
single particle size [38,40].
Figure 5 FTIR spectra of pure AAT (a), PLGA 50:50 (b), PLGA 75:25 (c), nonaqueous emulsion made α1AT-loaded PLGA (d), double
emulsion made α1AT-loaded PLGA (50:50) and (75:25)(e and f, respectively).
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the probability that at least one fraction of the aerosol
will reach the desired region of the lung.
As the imbalance of proteases and anti-proteases in
the lungs is an important factor in the pathogenesis of
COPD and other pulmonary diseases [12,13,16], hence,
the main candidate for pulmonary delivery is the mainlung anti-protease, α1AT. The necessity of the anti-pro-
tease presence in the lung for controlling the increase in
activity of elastase during inflammation is important.
Therefore in order to obtain such results, drug delivery
strategy must be based on the type of particle (lipid or
polymer), particle size, dispersity, stability, efficiency and
efficient drug release at appropriate times. For the best
Figure 6 DSC thermograms PLGA, and α1AT -loaded PLGA nanoparticles: (a) PLGA 50:50; (b) PLGA 75:25; (c) α1AT -loaded
nanoparticles prepared by nonaqueous emulsion method; (d) α1AT -loaded nanoparticles prepared by double emulsion method.
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be released in sufficient amounts in different parts of the
lungs in COPD patients. The released drug must per-
form its anti-protease activity locally and be absorbed ef-
ficiently by the lung epithelial membrane to raise
appropriate concentrations of the anti-protease in the
interstitial space (the main target place of protease) and
blood for further support.
In this project, the evaluation of α1AT release and par-
ticle properties for the purpose of α1AT aerosolization
was carried out. We used PLGA because drug release
can be controlled by its molecular weight and the ratio
of lactide to glycolide used for the polymerization. PLGA
has been approved as a safe polymer because it under-
goes hydrolysis to form lactic and glycolic acids. Lactic
acid is degraded to carbon dioxide and water throughFigure 7 Cor L105 lung epithelial-like cells before and after treatmencitric acid and glycolic acid is excreted with urine or oxi-
dized to glyoxylic acid [20,25-28].
The results of this study showed that the release pro-
files for PLGA at the 50:50 and 75:25 ratios were differ-
ent. By using PLGA at the 50:50 ratios, fast degradability
kinetics was obtained. The initial burst was higher with
PLGA 50:50 but the slow release period was more
extended when using PLGA at the 75:25 ratios. The in-
duction period and final release period are quite similar
in both polymers. In the other words, using these two
ratios of polymeric monomers together sufficient release
of anti-protease for efficient function will be obtained
[25,26,30,31].
Meanwhile, the amount of drug to PLGA of 5/25 mg
was selected to obtain the desirable loading efficiency,
mean particle size and distribution and drug releaset with nanoparticles.
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get organ. For example for oral recombinant drug deliv-
ery which needs particle and loaded protein-based drug
absorption through the intestine, particles' diameter
must not exceed 10 μ because larger particles cannot be
absorbed by the M-cell containing Peyer's patch in the
intestine via endocytosis. In the lungs, different endo-
cytosis and phagocytosis mechanisms also exist based on
the cells' distribution. Particle sizes ranging from 0.5 to
2 μ are phagocytized by lung macrophages. Furthermore,
ultrafine particles may be endocytized by lung endothe-
lial cells, which then enter blood circulation. The local
neutrophil elastase inhibitory effect of α1AT is mainly in
the interstitial and alveolar spaces, with the entrance to
blood circulation being less important. Therefore, par-
ticle sizing for aerosol purposes is very important in the
distribution, delivery and release of the carried drug.
α1AT delivery requires accessibility of drug to the lower
and middle respiratory tracts which need the endocyto-
sis process. Therefore the particles' dispersity with a size
range of 100 to 1000 nm is very suitable for drug deliv-
ery. As a result, the preparation method of nanoparticles
must account for the size polydispersity (Figure 8).
The results obtained in this study showed a mean par-
ticle size of 300 nm, and as mentioned previously, in this
heterogenic mixture of particles, most particles had a
diameter less than 500 nm which is an appropriate size
for endocytosis by the lung endothelial cells. The endo-
cytosis process causes the entrance and release of α1AT
into the interstitial spaces where neutrophil elastase se-
cretion affects elastin, therefore, leading to a targeted
treatment. On the other hand, particles with more than
500 nm in diameter reside in the alveolar region and the
released drug inhibits the elastase secreted by neutro-
phils in this region.
In addition to the location of release, the amount of
drug to be released must be in proportion to the severity
of inflammations at a specific period of time. The
threshold concentration of AAT in circulation is 11 μM,
therefore, we can assume this level as a protective con-
centration for the lungs against protease invasions dur-
ing inflammation. For this purpose, the amount of drug
release for obtaining the threshold concentration at a
specific period of time must be in a range that does not
impair the function of functional lung cells, such as the
alveolar epithelial and endothelial cells. One of the pos-
sible problems is the amount of particles carrying this
concentration of drug. For the investigation of this mat-
ter, we assume that if the drug release efficiency was
only %10, therefore to investigate the toxic effect, the
tenfold higher amount of loaded PLGA was applied to
ensure the concentration of 11 μM. Cor L105 cells were
treated with different concentrations of loaded nanopar-
ticles and results show no toxicity toward the cells.Conclusions
In summary, a protein loaded-PLGA nanoparticles was
synthesized. In synthesis procedure (2-hydroxypropyl)-β-
cyclodextrin and threhalose were employed which de-
crease loss of protein activity and act as cryoprotactant,
respectively. Nanoparticles have a wide range of particle
size which can be deposit in different parts of the re-
spiratory system especially in the deep lung. Various lac-
tide to glycolide ratio of the copolymer shows different
release profile of the drug which can significantly covers
extended and rapid drug release in one formulation.
Nanosized particles enable the drug to reach deep into
the lungs for maximum benefit. This mix formulation
shows a great potential for protein drug delivery in pul-
monary diseases especially in obstructive lung disease
for rapid, direct and extended delivery of drug allowing
high local drug concentrations.
Material and methods
Materials
Poly (D, L-lactide-co-glycolide) (PLGA), with a copoly-
mer ratio of lactide: glycolide 50:50 (Mw 40,000-75,000)
and 75:25 (Mw 66,000-107,000) were purchased from
Sigma Aldrich (USA). Poly (vinyl alcohol) (PVA) with a
molecular weight of 89,000-98,000 and Hydroxypropyl-
β-cyclodextrin (HP-β-CD) were obtained from Sigma
Aldrich (USA).
Alpha one-antitrypsin from human plasma and 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium brom-
ide (MTT) were bought from Sigma-Aldrich (St. Louis,
MO, USA). RPMI 1640, fetal bovine serum (FBS), glu-
tamine and penicillin/streptomycin were obtained from
Gibco BRL (now part of Invitrogen Corporation, Carls-
bad, CA, USA).
Methylene chloride, acetone, Span80, n-hexane, viscous
Paraffin, Acetonitrile and DMSO were purchased from
Merck (Germany). All reagents were of analytical grade.
Methods of preparation
In this study Alpha one-antitrypsin (α1AT) loaded parti-
cles were prepared by two different techniques (Figure 9):
Nonaqueous emulsion technique
Briefly, this technique is carried out by dissolving 25mg of
PLGA (50:50 and 75:25) in 3ml of acetonitrile. The solu-
tion was stirred for 30 min. 5mg of α1AT was dissolved
in double distilled water and was added drop-wise to
the abovementioned solution. The mixture was poured
drop- wise into 50ml of high viscosity paraffin contain-
ing 400 μl of %1 v/v Span80 and the resulting mixture
was stirred 500rpm for 4 hours to at room temperature
using a magnetic stirrer to ensure solvent evaporation
and nanoparticle hardening. Nanoparticles were col-
lected by centrifuge at 20000 rpm for 45 min, washed
Figure 8 a schematic representation of nanoparticle passage and decomposition in lung.
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(LaboGene ScanVac CoolSafe freeze dryer) using 2.5%
trehalose dihydrate as cryoprotectant and stored at
-20° C [41].Double emulsion technique
In this method 5 mg of protein was dissolved in 0.5 ml
of citrate buffer (pH=8) containing 0.5 mg/ml BSA solu-
tion and 5% (2-hydroxypropyl)-β-cyclodextrin, which
was previously reported to decrease loss of protein activ-
ity in interior water phase [42]. The protein solution was
emulsified with 3ml of 3:1 methylene chloride: aceton
containing 25 mg of PLGA (50:50). Emulsification was
carried out by ultrasonicator (Elmasonic S 60 (H), Elma,
Elma Hans Schmidbauer GmbH & Co. KG, Germany) at
amplitude of 5 for 20 seconds in an ice-cooled bath. The
w/o primary emulsion was added to 10 ml of 2% (w/v)
aqueous PVA in a drop-wise manner and then emulsi-
fied with high speed hemogenizer for 2 min at 10000
rpm. The w/o/w double emulsion was added to 80ml
double distilled water and was stirred in 500 rpm for 2
hours to allow the solvent evaporation. The hardened
nanoparticles were collected by centrifuge at 20000 rpm
for 45 min and washed thrice with sterile deionizedwater. Finally particles were freeze-dried using 2.5% tre-
halose dihydrate as cryoprotectant.α1AT –loaded nanoparticle characterization
Scanning electron microscopy observation
Scanning electron microscopy (SEM) was performed
using TESCAN Vega LMU (USA) for morphology
examination. One drop of concentrated 2 mg/ml aque-
ous suspension samples were deposited on aluminum
stubs and dried in a desiccator at room temperature to
obtain a uniform layer of nanoparticles. Samples were
coated with a 15 nm of gold layer using EMITECH
K450X sputter-coater (England). Coating was done at 20
mA for 2 min.Determination of particle size distribution
The laser dynamic light scattering (DLS) technique was
used for the determination of particle mean diameter
and distribution. Samples were prepared by suspending
5mg of each sample in 5 ml of sterile deionized water
and sonicated at amplitude of 40 and 0.5-sec pulse cycle
for 5 min (Hielscher ultrasonics GmbH, Germany). Mea-
surements were carried out using SEMATECH light
Figure 9 Two different methods of nanoparticle preparation by a) double emulsion and b) nonaqueous emulsion technique.
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temperature.
X-Ray diffraction (XRD) measurement
X-ray powder diffraction patterns were measured using
a Siemens FK 60-04 diffractometer (France). Measure-
ments were carried out with Fe-Kα radiation at 35 Kvand 25 mA. Film samples were scanned continuously
over an angular range between 4° and 90° (2θ) with a
step size of 0.02°. The scan step time was 1.2°/min.
Encapsulation efficiency
Encapsulation efficiency was determined by hydrolyzing. 5
mg of prepared nanoparticle was dissolved in 0.5 ml of
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solution was neutralized by adding 0.5ml of hydrochloric
acid 1M. The solution was centrifuged for 5 min at
13000 rpm and the supernatant was analyzed for
α1AT content. Protein concentration is determined by
measuring intrinsic fluorescence using fluorescence
spectrophotometer (Varian Cary Eclipse, Australia).
The fluorescence intensity of the samples is measured
from a standard curve (Additional file 1: Table S1). A
series of dilutions ranging from 2.5 to 200 μg/ml of
α1AT were made using phosphate buffer saline (PBS),
pH 7.4 as diluent.
Encapsulation efficiency was determined by subtracting
the total amount of protein added during synthesis from
the concentration of protein obtained through standard
curve.
In vitro release profile
For drug release studies 10mg of lyophilized A1AT
loaded PLGA obtained from different techniques were
suspended in 1ml of PBS pH 7.4 in a 2 ml eppendrof
tube by sonication at amplitude of 40 and 0.5-sec pulse
cycle for 2 min. Tubes were placed in shaker water bath
(Memmert, Germany) with constant shaking of 100
strokes per minute in 37°C. At different time intervals,
samples were centrifuged (Sigma microfuge, Germany)
at 13000 rpm for 20 min; aliquots of 500 μl were with-
drawn and replaced with the same volume of fresh PBS.
Particles were re-dispersing each time. The amount of
released α1AT was determined by measuring intrinsic
fluorescence mentioned above.
Protein polymer interaction study
The Fourier transformed infrared (FTIR) spectroscopy of
α1AT, PLGA and α1AT-loaded PLGA particles were car-
ried out with Bruker Tensor 27 (Bruker Optik, Germany)
in order to evaluate the kind of possible chemical inter-
action occurring between protein and polymer. The absorp-
tion peaks in infrared spectrum show the frequencies of
vibrations between bonds of atoms constituting the mater-
ial. For sample preparation few drops of pure PLGA (50:50
and 75:25) in acetonitrile and pure α1AT were placed onto
KBr pellets and the absorbance was scanned over the range
of 3600-600 cm1 at a resolution of 4 cm1 at room
temperature. Lyophilized α1AT-loaded PLGA particles
were ground into powder and mixed with IR grade KBr to
produce pellet. The background was obtained against pure
KBr pellet.
Differential scanning Calorimetry measurement
Differential Scanning Calorimetry (DSC) was carried out
by NETZSCH DSC 200 F3 Maia, Germany to investigate
the thermal property of protein inside the particles. 5
mg of α1AT, PLGA and α1AT-loaded PLGA particleswere weighted and loaded onto a standard aluminum
pans (2mm high & 4mm diameter). Samples were cooled
to -80°C and heated from 25°C to 250°C with a heat flow
rate of 10°C/min. Calibration was carried out by an
aluminum pan as a reference.
Cell culture
Human lung epithelial-like cells, Cor L105 (cell collec-
tion of Pasteur Institute, Iran) were cultivated in RPMI
1640 media supplemented with 10% heat-inactivated FBS
and 2 mM L-glutamine , NaHCO3 and 100 units/mL
penicillin, 100 mg/mL streptomycin at 37° in O2 5%/CO2
5% and 95% humidity. The medium was replenished and
the cells were subcultured by trypsinization.
Evaluation of Cytotoxicity
To determine the cytotoxic effect of loaded nanoparticles
on cell growth, 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) cell viability assay, which
assesses the mitochondrial activity in living cells, was car-
ried out. Cor-L105 human lung epithelial–like cells were
plated at a density of 4 × 104 cells/well on a 96-well plate
for 24 hours in a humidified incubator at 37°C and %5
CO2. Then, cells were treated with different nanoparticle
concentration of 0 to 1.5 mg/ml for 24 hours. Selected
concentrations correspond to protective threshold of α1AT
which is 11μM or 0.8 mg/ml. Cells which were incubated
only in culture medium were used as control. After 24
hours, cells were washed with fresh PBS and inhibition
in cell growth was assessed by adding 25μl of the MTT
solution (5 mg/mL in PBS) to each well. Absorbance
was measured at 540 nm with microplate reader.
Additional files
Additional file 1: Table S1. Standard curve for determination of protein
concentration
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